Publications by authors named "M Girardi"
Cutaneous T cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that can involve the skin, along with lymph nodes and blood. The two most common subtypes of CTCL are mycosis fungoides and Sézary syndrome, Since the initial description of mycosis fungoides by Dr. Jean-Louis Alibert in 1806, there have been significant advances in our understanding of the pathogenesis of CTCL, its diverse clinical and histologic variants, and the evolving treatment landscape.
View Article and Find Full Text PDFChanges in land use, climate, and host community are leading to increased complexity in eco-epidemiological relationships and the emergence of zoonoses. This study investigates the changes in the prevalence of several Ixodes ricinus-transmitted pathogens in questing ticks over a 10-year interval (2011-2013, 2020) in natural and agricultural habitats of the Autonomous Province of Trento (North-eastern Alps), finding an average prevalence of infection of 27.1%.
View Article and Find Full Text PDFArticle Synopsis
- - Benzoyl peroxide (BPO), commonly used in acne treatments, can degrade into benzene, a harmful carcinogen, especially when stored or used at high temperatures.
- - A study detected varying levels of benzene (0.16 to 35.30 ppm) in 111 over-the-counter BPO products when kept at room temperature, while a prescription version showed none at low temperatures but significant benzene at high temperatures.
- - Experiments revealed that using BPO on skin models can lead to detectable benzene levels in the air, especially under UV light, highlighting health risks from benzene exposure regardless of the initial concentration in the products.
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
September 2024
Article Synopsis
- T-cell lymphomas are complex cancers with generally poor outcomes, and the study focuses on the effectiveness of the EPOCH chemotherapy regimen among patients with aggressive cases, including both peripheral and cutaneous types.
- Out of 38 patients treated, the overall response rate (ORR) was 77%, with over half achieving complete remission, showing similar effectiveness across different racial backgrounds but varying success based on CD30 status.
- The EPOCH regimen demonstrated good safety and tolerance, making it a promising option for both newly diagnosed and relapsed/refractory T-cell lymphoma patients.